Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.
|Podcasts|September 1, 2020
AUPN Leading Edge Episode 2: So You Want to Be a Dean? Pros, Cons, Joys and Tribulations
Author(s)Clifton L. Gooch, MD, Charles Lockwood, MD
AUPN Leading Edge Episode 2 features Clifton Gooch, MD, and Charles Lockwood, MD, who explore making the leap from chair to dean. [LISTEN TIME: 25 minutes]
Advertisement
AUPN’s Leading Edge will focus on issues of interest and practical use to Neurology Department Chairs, and will be freely available on Apple’s iTunes, Spotify and Google.
In this episode, Clifton Gooch, MD, professor and Chair of Neurology at the University of South Florida Morsani College of Medicine, explores making the leap from chair to dean with Charles Lockwood, MD, dean of the USF Morsani College of Medicine and Senior Vice President of USF Health.
Advertisement
Related to this article
The clinical professor of neurology and pediatrics at The Ohio State University Wexner Medical Center discussed payer step therapy, earlier preventive treatment, and questions the updated guideline leaves open.
Brian Snelling, MD, director of the stroke program at Marcus Neuroscience Institute discussed delays in calling 911 after stroke onset, gaps in awareness of atypical symptoms, and how to reach underserved populations.
The Editor-in-Chief of the Journal of the American Heart Association discussed what journal editors look for in stroke research submissions, how AI and open access are reshaping publishing, and the equity gaps that still exist for researchers in lower-income countries.
Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, discusses the Neuromuscular Advocacy Collaborative, its growing year-round presence, and what the group hopes to accomplish heading into the 2027 MDA Clinical and Scientific Conference.
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA
2
AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS
3
Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study
4
Assessing Long-Term Disease Control With Nipocalimab in Pediatric Generalized Myasthenia Gravis: Jonathan Strober, MD
5